Roberto Lanes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/653324/publications.pdf

Version: 2024-02-01

82 2,092 26 44 papers citations h-index g-index

85 85 85 1641 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	<p>Metabolic Syndrome as a Risk Factor for Sensorineural Hearing Loss in Adult Patients with Turner Syndrome</p> . The Application of Clinical Genetics, 2020, Volume 13, 25-35.	3.0	6
2	<p>Anthropometric variables as cardiovascular risk predictors in a cohort of adult subjects with Turner syndrome</p> . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 1795-1809.	2.4	11
3	Near Adult Height in Girls with Turner Syndrome Treated with Growth Hormone Following Either Induced or Spontaneous Puberty. Journal of Pediatrics, 2019, 212, 172-179.e1.	1.8	9
4	Epigenetics in Turner syndrome. Clinical Epigenetics, 2018, 10, 45.	4.1	47
5	Alternatives in the Treatment of Short Stature. Advances in Pediatrics, 2017, 64, 111-131.	1.4	8
6	GH/IGF-1 Signaling and Current Knowledge of Epigenetics; a Review and Considerations on Possible Therapeutic Options. International Journal of Molecular Sciences, 2017, 18, 1624.	4.1	29
7	Metabolic Benefits of Growth Hormone Therapy. , 2016, , 79-92.		О
8	Cardiovascular Risk in Growth Hormone Deficiency. Endocrinology and Metabolism Clinics of North America, 2016, 45, 405-418.	3.2	15
9	Elevated secondâ€trimester maternal serum βâ€human chorionic gonadotropin and amniotic fluid alphaâ€fetoprotein as indicators of adverse obstetric outcomes in fetal Turner syndrome. Journal of Obstetrics and Gynaecology Research, 2015, 41, 1891-1898.	1.3	5
10	Higher prevalence of obesity and overweight without an adverse metabolic profile in girls with central precocious puberty compared to girls with early puberty, regardless of GnRH analogue treatment. International Journal of Pediatric Endocrinology (Springer), 2014, 2014, 5.	1.6	35
11	Effect of the parental origin of the X-chromosome on the clinical features, associated complications, the two-year-response to growth hormone (rhGH) and the biochemical profile in patients with turner syndrome. International Journal of Pediatric Endocrinology (Springer), 2013, 2013, 10.	1.6	18
12	Is the growth outcome of children with idiopathic short stature and isolated growth hormone deficiency following treatment with growth hormone and a luteinizing hormone-releasing hormone agonist superior to that obtained by GH alone?. Journal of Pediatric Endocrinology and Metabolism, 2012, 25, 651-7.	0.9	7
13	Consenso Latinoamericano: niños pequeños para la edad gestacional. Revista Chilena De Pediatria, 2012, 83, 620-634.	0.4	4
14	Latin American Consensus: Children Born Small for Gestational Age. BMC Pediatrics, 2011, 11, 66.	1.7	51
15	Limited Weight Loss or Simply No Weight Gain following Lifestyle-Only Intervention Tends to Redistribute Body Fat, to Decrease Lipid Concentrations, and to Improve Parameters of Insulin Sensitivity in Obese Children. International Journal of Pediatric Endocrinology (Springer), 2011, 2011, 241703.	1.6	7
16	Sex hormone priming. Journal of Pediatric Endocrinology and Metabolism, 2011, 24, 7-8.	0.9	3
17	GHR and VDR Genes do not Contribute to the Growth Hormone (GH) Response in GH Deficient and Turner Syndrome Patients. Journal of Pediatric Endocrinology and Metabolism, 2010, 23, 773-82.	0.9	8
18	Maintenance of Weight or Modest Weight Loss Following Lifestyle-Only Intervention Tends To Redistribute Body Fat, Decrease Lipid, CRP and Fibrinogen Levels and To Improve Parameters of Insulin Sensitivity in Obese Children, 2010,, P3-699-P3-699.		0

#	Article	IF	CITATIONS
19	The triglyceride/HDL-cholesterol ratio as a marker of cardiovascular risk in obese children; association with traditional and emergent risk factors. Pediatric Diabetes, 2008, 9, 464-471.	2.9	115
20	Circulating Levels of High-Sensitivity C-Reactive Protein and Soluble Markers of Vascular Endothelial Cell Activation in Growth Hormone-Deficient Adolescents. Hormone Research, 2008, 70, 230-235.	1.8	15
21	Is Testosterone and Estrogen Priming Prior to Clonidine Useful in the Evaluation of the Growth Hormone Status of Short Peripubertal Children?. Journal of Pediatric Endocrinology and Metabolism, 2008, 21, 257-66.	0.9	25
22	Endothelial Dysfunction in Growth Hormone Deficiency. Journal of Pediatric Endocrinology and Metabolism, 2008, 21, 319-21.	0.9	1
23	Coronary artery calcification, serum lipids, lipoproteins, and peripheral inflammatory markers in adolescents and young adults with type 1 diabetes. Journal of Pediatrics, 2006, 149, 320-323.	1.8	17
24	Growth hormone deficiency, low levels of adiponectin, and unfavorable plasma lipid and lipoproteins. Journal of Pediatrics, 2006, 149, 324-329.	1.8	45
25	A GnRH analog test in diagnosing gonadotropin deficiency in males with delayed puberty. Journal of Pediatrics, 2006, 149, 731.	1.8	2
26	Relationship Between Different Fasting-Based Insulin Sensitivity Indices in Obese Children and Adolescents. Journal of Pediatric Endocrinology and Metabolism, 2006, 19, 259-65.	0.9	24
27	Endothelial Function, Carotid Artery Intima-Media Thickness, Epicardial Adipose Tissue, and Left Ventricular Mass and Function in Growth Hormone-Deficient Adolescents: Apparent Effects of Growth Hormone Treatment on These Parameters. Journal of Clinical Endocrinology and Metabolism, 2005. 90. 3978-3982.	3.6	80
28	Leptina en relaciÃ ³ n con el sexo, el Ãndice de masa corporal, el estadio puberal y la insulina en niños con déficit de hormonas de crecimiento con y sin tratamiento sustitutivo. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2005, 52, 277-282.	0.8	0
29	Female Pseudohermaphroditism with Phallic Urethra in the Offspring of a Mother with an Adrenal Tumor. Journal of Pediatric Endocrinology and Metabolism, 2004, 17, 1571-4.	0.9	3
30	Accelerated Versus Slowly Progressive Forms of Puberty in Girls with Precocious and Early Puberty. Gonadotropin Suppressive Effect and Final Height Obtained with Two Different Analogs. Journal of Pediatric Endocrinology and Metabolism, 2004, 17, 759-66.	0.9	29
31	Long-Term Outcome of Growth Hormone Therapy in Children and Adolescents. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2004, 3, 53-66.	1.8	35
32	Decreased final height of children with growth deceleration secondary to poor weight gain during late childhood. Journal of Pediatrics, 2004, 145, 128-130.	1.8	7
33	Peripheral inflammatory and fibrinolytic markers in adolescents with growth hormone deficiency: Relation to postprandial dyslipidemia. Journal of Pediatrics, 2004, 145, 657-661.	1.8	32
34	Molecular analysis in Turner syndrome. Journal of Pediatrics, 2003, 142, 336-340.	1.8	56
35	Cardiovascular Risk of Young Growth-Hormone-Deficient Adolescents. Hormone Research in Paediatrics, 2003, 60, 291-296.	1.8	32
36	Cardiac Mass and Function, Carotid Artery Intima-Media Thickness and Lipoprotein (a) Levels in Children and Adolescents with Type I Diabetes Mellitus of Short Duration. Journal of Pediatric Endocrinology and Metabolism, 2002, 15, 181-6.	0.9	38

#	Article	IF	CITATIONS
37	Is insulin-like growth factor-1 monitoring useful in assessing the response to growth hormone of growth hormone-deficient children?. Journal of Pediatrics, 2002, 141, 606-610.	1.8	18
38	Hypoglycemia associated with clonidine testing. Journal of Pediatrics, 2002, 140, 937-938.	1.8	0
39	The effect of short- and long-term growth hormone treatment on bone mineral density and bone metabolism of prepubertal children with idiopathic short stature: a 3-year study. Clinical Endocrinology, 2002, 57, 725-730.	2.4	28
40	Decreased Bone Mineral Density and Bone Formation Markers Shortly After Diagnosis of Clinical Type 1 Diabetes Mellitus. Journal of Pediatric Endocrinology and Metabolism, 2001, 14, 525-8.	0.9	92
41	Cardiac Mass and Function, Carotid Artery Intima-Media Thickness, and Lipoprotein Levels in Growth Hormone-Deficient Adolescents. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1061-1065.	3.6	68
42	Final Adult Height in Short Healthy Children Treated with Growth Hormone and Gonadotropin-Releasing Hormone Analogs. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 458-458.	3.6	12
43	Cardiac Mass and Function, Carotid Artery Intima-Media Thickness, and Lipoprotein Levels in Growth Hormone-Deficient Adolescents. Plant Systematics and Evolution, 2001, 86, 1061-1065.	0.9	20
44	A longitudinal study on bone mineral density until adulthood in girls with Turner's syndrome participating in a growth hormone injection frequency-response trial. Clinical Endocrinology, 2000, 53, 760-761.	2.4	0
45	Growth Velocity, Final Height and Bone Mineral Metabolism of Short Children Treated Long Term with Growth Hormone. Current Pharmaceutical Biotechnology, 2000, 1, 33-46.	1.6	15
46	Growth Hormone Treatment in Patients with Intrauterine Growth Retardation. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1345-1346.	3.6	0
47	Acipimox, a Nicotinic Acid Analog, Stimulates Growth Hormone Secretion in Short Healthy Prepubertal Children. Journal of Pediatric Endocrinology and Metabolism, 2000, 13, 1115-20.	0.9	5
48	Bone mineral density and Turner's syndrome—any lessons to be learned about "menopausal osteoporosis― commentary. Fertility and Sterility, 2000, 74, 844.	1.0	0
49	Bone mineral density and Turner's syndrome—any lessons to be learned about "menopausal osteoporosis― the reply. Fertility and Sterility, 2000, 74, 844-845.	1.0	0
50	Growth Hormone Treatment in Patients with Intrauterine Growth Retardation. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1345a-1346.	3.6	1
51	Circulating lodide Concentrations during and after Pregnancy. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1345-1345.	3.6	0
52	Bone, chronic renal failure and GH treatment. Clinical Endocrinology, 1999, 51, 131-131.	2.4	0
53	Decreased trabecular bone mineral density in children with idiopathic short stature: Normalization of bone density and increased bone turnover after 1 year of growth hormone treatment. Journal of Pediatrics, $1999, 135, 177-181$.	1.8	19
54	Decreased bone mass despite long-term estrogen replacement therapy in young women with Turner's syndrome and previously normal bone density. Fertility and Sterility, 1999, 72, 896-899.	1.0	43

#	Article	IF	CITATIONS
55	Final height after combined growth hormone and gonadotrophinâ€releasing hormone analogue therapy in short healthy children entering into normally timed puberty. Clinical Endocrinology, 1998, 49, 197-202.	2.4	56
56	Effectiveness and Limitations of the Use of the Gonadotropin-Releasing Hormone Agonist Leuprolide Acetate in the Diagnosis of Delayed Puberty in Males. Hormone Research, 1997, 48, 1-4.	1.8	24
57	Serum lipids, lipoprotein lp(a), and plasminogen activator inhibitor-1 in patients with Turner's syndrome before and during growth hormone and estrogen therapy. Fertility and Sterility, 1997, 68, 473-477.	1.0	36
58	Effect of Glycemic Control on the Growth Velocity and Several Metabolic Parameters of Conventionally Treated Children with Insulin Dependent Diabetes Mellitus. Journal of Pediatric Endocrinology and Metabolism, 1996, 9, 569-75.	0.9	16
59	Changes in Bone Mineral Density, Growth Velocity and Renal Function of Prepubertal Uremic Children during Growth Hormone Treatment. Hormone Research, 1996, 46, 263-268.	1.8	22
60	Bone Mineral Density of Prepubertal Age Girls with Turner's Syndrome While on Growth Hormone Therapy. Hormone Research, 1995, 44, 168-171.	1.8	45
61	Short- and long-term effect of oral salbutamol on growth hormone secretion in prepubertal asthmatic children. Metabolism: Clinical and Experimental, 1995, 44, 149-151.	3.4	8
62	ACTH Stimulation Tests and Plasma Dehydroepiandrosterone Sulfate Levels in Women with Hirsutism. Obstetrical and Gynecological Survey, 1991, 46, 117.	0.4	0
63	ACTH Stimulation Tests and Plasma Dehydroepiandrosterone Sulfate Levels in Women with Hirsutism. New England Journal of Medicine, 1990, 323, 849-854.	27.0	103
64	Growth Hormone Secretion in Pubertal Age Patients with Turner's Syndrome. Journal of Clinical Endocrinology and Metabolism, 1990, 71, 770-772.	3.6	22
65	Growth Hormone Release in Response to Growth Hormone-Releasing Hormone in Term and Preterm Neonates. Neonatology, 1989, 56, 252-256.	2.0	8
66	Diagnostic Limitations of Spontaneous Growth Hormone Measurements in Normally Growing Prepubertal Children. JAMA Pediatrics, 1989, 143, 1284.	3.0	15
67	The metoclopramide test: a useful tool with the luteinizing hormone-releasing hormone test in distinguishing between constitutional delay of puberty and hypogonadotropic hypogonadism. Fertility and Sterility, 1989, 52, 55-59.	1.0	6
68	HCG Stimulation in Children With Cryptorchidism. Clinical Pediatrics, 1987, 26, 512-514.	0.8	12
69	Growth hormone secretion in patients with constitutional delay of growth and pubertal development. Journal of Pediatrics, 1986, 109, 781-783.	1.8	37
70	Effect of Asphyxia on Free Thyroid Hormone Levels in Full Term Newborns. Pediatric Research, 1985, 19, 1305-1307.	2.3	13
71	Low-Dose Oral Clonidine. American Journal of Diseases of Children, 1985, 139, 87.	0.5	49
72	Cortisol Levels and Clonidine Administration. JAMA Pediatrics, 1985, 139, 9.	3.0	0

ROBERTO LANES

#	Article	IF	CITATIONS
73	A Clinical Syndrome of Mild Androgen Insensitivity*. Journal of Clinical Endocrinology and Metabolism, 1984, 59, 672-678.	3.6	37
74	Abnormalities of thyroid function in infants with Down syndrome. Journal of Pediatrics, 1984, 104, 545-549.	1.8	172
75	Decreased secretion of cortisol and ACTH after oral clonidine administration in normal adults. Metabolism: Clinical and Experimental, 1983, 32, 568-570.	3.4	65
76	Clonidine is a better test of growth hormone deficiency. Archives of Disease in Childhood, 1983, 58, 754-754.	1.9	1
77	Sibship with 17-Ketosteroid Reductase (17-KSR) Deficiency and Hypothyroidism. Lack of Linkage of Histocompatibility Leucocyte Antigen and 17-KSR Loci*. Journal of Clinical Endocrinology and Metabolism, 1983, 57, 190-196.	3.6	18
78	Turner syndrome patients with a ring X chromosome. Clinical Genetics, 1983, 23, 447-453.	2.0	19
79	Adrenal Cortical Carcinoma in a 4-Year-Old Child. Clinical Pediatrics, 1982, 21, 164-166.	0.8	5
80	Oral clonidine â€" an effective growth hormone-releasing agent in prepubertal subjects. Journal of Pediatrics, 1982, 100, 710-714.	1.8	98
81	Dwarfism Associated with Normal Serum Growth Hormone and Increased Bioassayable, Receptorassayable, and Immunoassayable Somatomedin. Journal of Clinical Endocrinology and Metabolism, 1980, 50, 485-488.	3.6	50
82	Persistence of the enzymatic block in adolescent patients with salt-losing congenital adrenal hyperplasia. Journal of Pediatrics, 1979, 95, 534-537.	1.8	12